Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation "PRAGUE-17"

Recruiting

Phase 4 Results N/A

Summary of Purpose

Atrial fibrillation (AF) is the most common cardiac arrhythmia with a prevalence of 1-2%. Without antithrombotic treatment, the annual risk of a cardioembolic event is 5-6%. The source of a cardioembolic event is a thrombus, which usually forms in the left atrial appendage (LAA). The prevention of cardioembolic events involves treatment with anticoagulant drugs, which were limited to, until recently, vitamin K...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 31 July 2016.

1 Apr 2015 16 Apr 2015 1 May 2018 1 May 2020 1 Jul 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Open Label
  • Purpose: Prevention
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

Not available